Infectious Diseases

  • Jan von Overbeck


The impact of SARS on society and the economy was enormous, especially in Asia. This type of epidemic is not new, but the media reaction had considerable impact. For society, the investigation of an unfolding epidemic is essential to assess the potential impact and to implement measures to contain it. The insurance business is faced with the same necessities, and to determine early whether it should adapt its business processes.1 In recent years, the infectious disease threat has diverged considerably from its previous patterns of epidemiology. As a result, new pathogens, or newly recognized diseases involving known pathogens, are being reported at an unprecedented rate. The phenomenal growth of international travel and trade has vastly increased the speed and ease with which pathogens and vectors can cross continents to cause outbreaks, epidemics and, on occasion, establish permanent residence in new areas. No country acting alone can defend its borders against this threat. Efficient defense requires a global system for gathering infectious disease intelligence, detecting outbreaks quickly and collaborating to contain their spread.


Human Immunodeficiency Virus West Nile Virus Severe Acute Respiratory Syndrome Acquire Immune Deficiency Syndrome Genital Ulcer Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    von Overbeck J. Insurance and epidemics: SARS, West Nile virus and Nipah virus. J Insur Med 2003; 35: 24–33.Google Scholar
  2. 2. (WHO, accessed 22 October 2003).
  3. 3.
    Swartz MN. Recognition and management of anthrax — an update. N Engl J Med 2001; 345: 1621–6.CrossRefGoogle Scholar
  4. 4.
    Shapiro RL et al. Botulism in the USA: a clinical and epidemiologic review. Ann Intern Med 1998; 129: 221–8.CrossRefGoogle Scholar
  5. 5.
    Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis 2001; 1:334–44.CrossRefGoogle Scholar
  6. 6.
    Sack D et al. Cholera. Lancet 2004; 363: 223–33.CrossRefGoogle Scholar
  7. 7.
    Stoddart B, Wilcox MH. Clostridium difficile. Curr Opin Infect Dis 2002; 15: 513–18.CrossRefGoogle Scholar
  8. 8.
    Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175–86.CrossRefGoogle Scholar
  9. 9.
    Fields BS et al. Legionella and Legionnaires’ disease: 25 years of investigation. Clin Microbiol Rev 2002; 15: 506–26.CrossRefGoogle Scholar
  10. 10.
    Ustianowski AP, Lockwood DN. Leprosy: current diagnostic and treatment approaches. Curr Opin Infect Dis 2003; 16:421–7.CrossRefGoogle Scholar
  11. 11.
    Bharti AR et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis 2003; 3: 757–71.CrossRefGoogle Scholar
  12. 12.
    Hengge UR et al. Lyme borreliosis. Lancet Infect Dis 2003; 3: 489–500.CrossRefGoogle Scholar
  13. 13.
    Krishna G, Chitkara RK. Pneumonic plague. Semin Respir Infect 2003; 18: 159–67.Google Scholar
  14. 14.
    Andrews J et al. Community-acquired pneumonia. Curr Opin Pulm Med 2003; 9: 175–80.CrossRefGoogle Scholar
  15. 15.
    Graham SM. Salmonellosis in children in developing and developed countries and populations. Curr Opin Infect Dis 2002; 15: 507–12.CrossRefGoogle Scholar
  16. 16.
    Frieden TR at al. Tuberculosis. Lancet 2003; 362: 887–99.CrossRefGoogle Scholar
  17. 17.
    Tufariello JM et al. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003; 3: 578–90.CrossRefGoogle Scholar
  18. 18.
    Davies PD. The world-wide increase in tuberculosis: how demographic changes, HIV infection and increasing numbers in poverty are increasing tuberculosis. Ann Med 2003; 35: 235–43.CrossRefGoogle Scholar
  19. 19.
    Corbett EL et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009–21.CrossRefGoogle Scholar
  20. 20.
    Ayan I et al. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol 2003; 4:13–21.CrossRefGoogle Scholar
  21. 21.
    Chien X et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001; 345:1877.CrossRefGoogle Scholar
  22. 22.
    Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 47–58.CrossRefGoogle Scholar
  23. 23.
    Alter MJ. Epidemiology and prevention of hepatitis B.Semin Liver Dis 2003; 23: 39–46.CrossRefGoogle Scholar
  24. 24.
    Kao JH and Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395–403.CrossRefGoogle Scholar
  25. 25.
    Mahomey FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351–66.Google Scholar
  26. 26.
    Yang HY et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168–74.CrossRefGoogle Scholar
  27. 27.
  28. 28.
    von Overbeck J. Hepatitis B infection. On the Risk 2002; 4: 50–61.Google Scholar
  29. 29.
    Flamm SL. Chronic hepatitis C virus infection.-JAMA. 2003; 289: 2413–7.CrossRefGoogle Scholar
  30. 30.
    Alter MJ et al. The natural history of community-acquired hepatitis C in the USA. N Engl J Med 1992; 327: 1899–1905.CrossRefGoogle Scholar
  31. 31.
    Alter MJ et al. The prevalence of hepatitis C virus infection in the USA, 1988 through 1994. N Engl J Med 1999; 341: 556–62.CrossRefGoogle Scholar
  32. 32.
    Freeman X et al. The natural history of chronic hepatitis C: a systematic review. Hepatology 34: 809–16.Google Scholar
  33. 33.
    Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340:1228–33.CrossRefGoogle Scholar
  34. 34.
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41–52.CrossRefGoogle Scholar
  35. 35.
    Pratt DS and Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Eng J Med 2000; 342: 1266–71.CrossRefGoogle Scholar
  36. 36.
    Shakil AO et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995; 123: 330–7.CrossRefGoogle Scholar
  37. 37.
    von Overbeck J. The silent hepatitis C epidemic. On the Risk 2001; 4: 58–67.Google Scholar
  38. 38.
    Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347: 340–6.CrossRefGoogle Scholar
  39. 39.
    Aylward RB et al. Global health goals: lessons from the worldwide effort to eradicate poliomyelitis. Lancet. 2003; 362: 909–14.CrossRefGoogle Scholar
  40. 40.
    Golden MR et al. Update on syphilis: resurgence of an old problem. JAMA 2003; 290: 1510–4.CrossRefGoogle Scholar
  41. 41.
    Walker DG, Walker GJ. Forgotten but not gone: the continuing scourge of congenital syphilis. Lancet Infect Dis 2002; 2: 432–6CrossRefGoogle Scholar
  42. 42.
    Daszak P et al. Emerging infectious diseases of wildlife — Threats to biodiversity and human health. Science 2000; 287: 443–9.CrossRefGoogle Scholar
  43. 43.
    Donnelly C et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003; 361: 1761–6.CrossRefGoogle Scholar
  44. 44.
    Peiris J et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767–72.CrossRefGoogle Scholar
  45. 45.
    A report of the National Advisory Committee on SARS and Public Health. Learning from SARS. Health Canada. 2003. Available at: Accessed on October 22, 2003.

Copyright information

© Dr R. D. C. Brackenridge, Dr Richard S. Croxson, Dr Ross Mackenzie 2006

Authors and Affiliations

  • Jan von Overbeck

There are no affiliations available

Personalised recommendations